Active Pharmaceutical Ingredients CDMO Market Size to Surpass US$ 236.1 Bn by 2030

The global Active Pharmaceutical Ingredients CDMO market size is expected to surpass around US$ 236.1 billion by 2030 from valued at US$ 91.6 billion in 2020 with a registered CAGR of 12.7% from 2021 to 2030.

The growth of small molecules, rising (API) complexity, and the need to reduce costs are factors contributing to the rapid expansion of outsourcing services in the pharmaceutical sector. Only a few companies have achieved global reach and scale in the Contract Development and Manufacturing Organization (CDMO) sector, which is still fragmented. Besides, many companies are providing one-stop-shop solutions as an integrated source of APIs and formulations.

Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38335

However, due to the COVID-19 pandemic, governments worldwide have opted to boycott APIs made in China. Due to government-imposed lockdown limitations in China, 44 firms were declared non-operational during the pandemic. As a consequence, various countries have launched programs to develop their own APIs, and countries across the EU have re-evaluated their healthcare models in order to combat the virus and ensure a steady supply of APIs.

Report Highlights

The traditional active pharmaceutical ingredient segment dominated the market and accounted for the largest revenue share of 50.5% in 2020. The highly potent APIs segment accounted for the significant largest revenue share of 39.5% in 2020. The growth is primarily driven by rising demand for targeted cancer and other treatments. Manufacturing and technology advancements, as well as manufacturer investments, are also contributing to the growth. The majority of HPAPIs are used in the development of anti-cancer medications. Most of HPAPIs are currently tiny molecules. However, more potent compounds are emerging at a faster rate.

The antibody-drug conjugate segment is anticipated to register a lucrative growth rate of 22.3% over the forecast period. The efficacy of Antibody Drug Conjugates (ADC) and checkpoint inhibitors in the fight against cancer is having a significant impact on ADC R&D.

The biotech segment is projected to register the fastest growth rate of 10.9% over the forecast period. Factors such as rising demand for biopharmaceuticals and higher molecular efficiency are propelling segment growth. Furthermore, large investments in the biotechnology and biopharmaceutical industries might be ascribed to the rise in the segment.

Check full Report ToC@ https://www.visionresearchreports.com/active-pharmaceutical-ingredients-cdmo-market/toc/38335

The innovative drugs segment dominated the market for active pharmaceutical ingredients CDMO and accounted for the largest revenue share of 84.6% in 2020. Increased FDA approvals for new molecular entities, the high cost of innovative active pharmaceutical ingredients relative to generic pharmaceuticals, and the increased focus on R&D are all contributing to segment growth. Many unique molecules are present in the pipeline as a result of extensive research in this subject and are projected to be launched during the forecast period.

The generics drugs segment is anticipated to witness the fastest CAGR of 10.5% during the forecast period. This is largely due to patent expiration and cost-effectiveness. The generic sector is growing as a result of the growing number of patents that are scheduled to expire.

The oncology segment dominated the market for active pharmaceutical ingredients CDMO and accounted for the largest revenue share of 45.1% in 2020. Cancer therapies are driving a significant share of biologics industry growth, as well as the Highly Potent API (HPAPI) sub-sector.

The glaucoma segment accounted for the largest revenue share of 11.0% in the market for active pharmaceutical ingredients CDMO in 2020. The segment is also projected to witness the fastest CAGR of 10.0% during the forecast period. This is largely attributed due to the rising prevalence of diabetes, the growing elderly population, and the increase in healthcare spending. Brinzolamide Ophthalmic Suspension, Nyxol (PhentolamineMesylate), and Ripasudil hydrochloride hydrate are among the prospective drugs in the Glaucoma pipeline. Some of these drugs have reached the end of their late clinical development stages, while others are still in the process.

Based on workflow, the commercial segment led the market for active pharmaceutical ingredients CDMO and accounted for the largest revenue share of 98.0% in 2020. The growth is largely attributed to the high revenue generation from the commercial active pharmaceutical ingredient production that accounts for 73.0% of commercial CDMO revenues, which is APIs’ larger market share a portion of the drug’s cost-of-goods in comparison to the drug’s product process of production.

The clinical segment is anticipated to witness the fastest CAGR of 9.1% in the market for active pharmaceutical ingredients CDMO during the forecast period. This is largely attributed due to a record number of molecules in the preclinical and clinical development pipelines of all sorts, as well as increased R&D spending. The late phase of clinical research has the most significant impact on the value generated by the CDMO pharmaceutical industry relationship.

Asia Pacific dominated the active pharmaceutical ingredients CDMO market and accounted for the largest revenue share of 56.4% in 2020. The segment is anticipated to register the fastest CAGR of 10.9% throughout the forecast period. The significantly cheaper manufacturing costs as compared to North America and Europe and favorable laws in the region particularly China and India are factors dominating the market for active pharmaceutical ingredients CDMO in the region. While China and India have established themselves as important providers of active pharmaceutical ingredient manufacturing services, the U.S. continues to be the principal outsourcing hub for pharmaceutical development. This is due to a combination of enormous amounts of financing and a unique concentration of university-affiliated pharmaceutical research hubs. The increased importance of conventional medications and the rapidly increasing occurrence of persistent infections are important factors for the Indian API market to grow favorably.

Key Players

• Cambrex
• Recipharm
• Thermo Fisher Pantheon
• Corden Pharma
• Samsung Biologics
• Lonza
• Catalent
• Siegfried
• Piramal Pharma Solutions
• BoehringerIngelheim

Market Segmentation

• Product Outlook
  • Traditional Active Pharmaceutical Ingredient (Traditional API)
  • Highly Potent Active Pharmaceutical Ingredient (HP-API)
  • Antibody Drug Conjugate (ADC)
  • Others

• Synthesis Outlook
  • Synthetic
  • Biotech

• Drug Outlook
  • Innovative
  • Generics

• Workflow Outlook
  • Clinical
  • Commercial

• Application Outlook
  • Oncology
  • Hormonal
  • Glaucoma
  • Cardiovascular
  • Diabetes
  • Others

• Regional Outlook
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Click Here to View Full Report Table of Contents

Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38335

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333